Surviving the digital therapeutics graveyard—and thriving | David Benshoof Klein, Click Therapeutics
Tuesday, October 13, 2026
Transcript intelligence
What OpenRounds heard
Source-grounded signals extracted from the episode transcript. Timestamps and supporting excerpts appear when available.
The speaker reports that Click Therapeutics has received its third FDA clearance for software as a treatment.
The speaker reports that AI in care delivery raises questions about the appropriate level of autonomy versus human supervision in provider-patient encounters.
“we're right now in this hot mess with ai being brought into care delivery and by that i mean being brought into a setting where a provider is working to a patient and how much should ai be useful in those encounters and at what point is it autonomous and at what point should it be supervised by a human being”
The speaker reports that Click Therapeutics conducts randomized controlled trials with sham controls and drug-like endpoints for its software treatments.
Christina Farr talks with David Benshoof Klein, Founder and CEO of Click Therapeutics, days after the FDA cleared Motivista, the first authorized treatment for the negative symptoms of schizophrenia. They discuss why so many digital therapeutics companies failed, and why an FDA-authorized app still has to fight for the coverage a drug would get automatically. David also explains why he thinks AI tools, not pharma sales reps, may be what puts treatments like Motivista in front of doctors.—SPONSOR:Click Therapeutics builds medical-grade patient software across digital therapeutics, software-enhanced drugs, wellness & wearables, and AI-enabled interventions. Its platform offers a library of 100+ validated modules backed by rigorous clinical testing, bringing biotech rigor to any condition with a neurological or behavioral component.To learn more about Click: https://www.clicktherapeutics.com/ To learn more about Motivista: https://www.motivista.com/%E2%80%94Join Christina for upcoming webinars:10/13 - Verifying AI in Medicine: Is Healthcare AI Actually Ready for Deployment? https://streamyard.com/watch/GwsSXwdikhMw 10/28 - Type 2 Diabetes & Cardiometabolic Care: Wearables, AI & GLP-1s https://streamyard.com/watch/uAuwCzUEJTCF 11/3 - Is It Finally the Moment for Alternative Plan Design? https://streamyard.com/watch/ereM3aB58XK4 —LINKS:FDA clears Motivista (CT-155): https://www.clicktherapeutics.com/news/fda-clears-motivista-ct-155-the-first-therapeutic-indicated-for-the-treatment-of-the-negative-symptoms-of-schizophrenia CT-132, Click’s episodic migraine program: https://www.clicktherapeutics.com/products/ct-132 FDA draft guidance, Regulatory Considerations for Prescription Drug Use-Related Software (PDURS): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-prescript ion-drug-use-related-software Click acquires Better Therapeutics’ assets, 2024: https://www.businesswire.com/news/home/20240522194752/en/Click-Therapeutics-Accelerates-Expansion-into-Obesity-and-Cardiometabolic-Disease-With-Acquisition-of-the-Assets-of-Better-Therapeutics-Inc Chrissy Farr on YouTube: https://www.youtube.com/@LiferswithChristinaFarr Chrissy Farr on Instagram: https://www.instagram.com/cfarr/ Subscribe to the Second Opinion Newsletter: https://secondopinion.media/ Chrissy’s Book: The Storyteller's Advantage: https://www.chrissyfarr.com/books —FOLLOW:David:https://www.linkedin.com/in/davidbklein/ Chrissy:https://www.linkedin.com/in/christinafarr/ https://x.com/chrissyfarr Second Opinion Media:https://www.instagram.com/second.opinion.media/ https://x.com/second_op_media —TIMESTAMPS:(00:00) Lead in(00:30) Intro(01:46) First for schizophrenia(02:20) What digital therapeutics means(04:01) Software treats disease(05:35) Drugs plus software(06:55) Negative symptoms explained(09:56) Designing adaptive goals(13:50) Safety and autonomy(16:03) Generative AI in care(22:48) Regulation and evidence(26:55) Digital therapeutics graveyard(27:51) Digital therapeutics graveyard(28:40) Why programs fail evidence(29:38) Click survival playbook(30:50) Commercialization and coverage(31:46) Pharma launch gap(33:42) AI driven prescribing wave(36:37) FDA guidance and pharma cycles(40:56) Pricing value and access(43:48) Hiring for scrappy commercial(46:38) Future of venture and consumers(51:31) OTC migraine and AI assistants(53:42) Text messaging engagement engine(55:15) Wrap
Show transcript excerpt
Christina Farr talks with David Benshoof Klein, Founder and CEO of Click Therapeutics, days after the FDA cleared Motivista, the first authorized treatment for the negative symptoms of schizophrenia. They discuss why so many digital therapeutics companies failed, and why an FDA-authorized app still has to fight for the coverage a drug would get automatically. David also explains why he thinks AI tools, not pharma sales reps, may be what puts treatments like Motivista in front of doctors.—SPONSOR:Click Therapeutics builds medical-grade patient software across digital therapeutics, software-enhanced drugs, wellness & wearables, and AI-enabled interventions. Its platform offers a library of 100+ validated modules backed by rigorous clinical testing, bringing biotech rigor to any condition with a neurological or behavioral component.To learn more about Click: https://www.clicktherapeutics.com/ To learn more about Motivista: https://www.motivista.com/—Join Christina for upcoming webinars:10/13 - Verifying AI in Medicine: Is Healthcare AI Actually Ready for Deployment? https://streamyard.com/watch/GwsSXwdikhMw 10/28 - Type 2 Diabetes & Cardiometabolic Care: Wearables, AI & GLP-1s https://streamyard.com/watch/uAuwCzUEJTCF 11/3 - Is It Finally the Moment for Alternative Plan Design? https://streamyard.com/watch/ereM3aB58XK4 —LINKS:FDA clears Motivista (CT-155): https://www.clicktherapeutics.com/news/fda-clears-motivista-ct-155-the-first-therapeutic-indicated-for-the-treatment-of-the-negative-symptoms-of-schizophrenia CT-132, Click’s episodic migraine program: https://www.clicktherapeutics.com/products/ct-132 FDA draft guidance, Regulatory Considerations for Prescription Drug Use-Related Software (PDURS): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-prescript ion-drug-use-related-software Click acquires Better Therapeutics’ assets, 2024: https://www.businesswire.com/news/home/20240522194752/en/Click-Therapeutics-Accelerates-Expansion-into-Obesity-and-Cardiometabolic-Disease-With-Acquisition-of-the-Assets-of-Better-Therapeutics-Inc Chrissy Farr on YouTube: https://www.youtube.com/@LiferswithChristinaFarr Chrissy Farr on Instagram: https://www.instagram.com/cfarr/ Subscribe to the Second Opinion Newsletter: https://secondopinion.media/ Chrissy’s Book: The Storyteller's Advantage: https://www.chrissyfarr.com/books —FOLLOW:David:https://www.linkedin.com/in/davidbklein/ Chrissy:https://www.linkedin.com/in/christinafarr/ https://x.com/chrissyfarr Second Opinion Media:https://www.instagram.com/second.opinion.media/ https://x.com/second_op_media —TIMESTAMPS:(00:00) Lead in(00:30) Intro(01:46) First for schizophrenia(02:20) What digital therapeutics means(04:01) Software treats disease(05:35) Drugs plus software(06:55) Negative symptoms explained(09:56) Designing adaptive goals(13:50) Safety and autonomy(16:03) Generative AI in care(22:48) Regulation and evidence(26:55) Digital therapeutics graveyard(27:51) Digital therapeutics graveyard(28:40) Why programs fail evidence(29:38) Click survival playbook(30:50) Commercialization and coverage(31:46) Pharma launch gap(33:42) AI driven prescribing wave(36:37) FDA guidance and pharma cycles(40:56) Pricing value and access(43:48) Hiring for scrappy commercial(46:38) Future of venture and consumers(51:31) OTC migraine and AI assistants(53:42) Text messaging engagement engine(55:15) Wrap
Daily healthcare AI brief
Get the free healthcare AI briefing
One concise briefing built from reporting, research, policy, blogs, videos, and full podcast transcripts.
Free. Get a sign-in link by email to finish subscribing. An account is created if needed. Unsubscribe anytime. Already subscribed? Sign in to save and personalize.